Enalapril in infants with single ventricle: results of a multicenter randomized trial.

ABSTRACT:

Background

Angiotensin-converting enzyme inhibitor therapy improves clinical outcome and ventricular function in adults with heart failure. Infants with single-ventricle physiology have poor growth and are at risk for abnormalities in ventricular systolic and diastolic function. The ability of angiotensin-converting enzyme inhibitor therapy to preserve ventricular function and improve somatic growth and outcomes in these infants is unknown.

Methods and results

The Pediatric Heart Network conducted a double-blind trial involving 230 infants with single-ventricle physiology randomized to receive enalapril (target dose 0.4 mg . kg(-1) . d(-1)) or placebo who were followed up until 14 months of age. The primary end point was weight-for-age z score at 14 months. The primary analy

SUBMITTER: Hsu DT 

PROVIDER: S-EPMC3692364 | biostudies-literature | 2010 Jul

REPOSITORIES: biostudies-literature